Yuksel Ulas, Ogden Mustafa, Ozdemir Alemiddin, Kisa Ucler, Bakar Bulent
Kirikkale University, Faculty of Medicine, Department of Neurosurgery, Yahsihan, Kirikkale, Turkey.
Kirikkale University, Faculty of Medicine, Department of Biochemistry, Kirikkale, Turkey.
J Med Biochem. 2021 Jan 26;40(1):67-73. doi: 10.5937/jomb0-24722.
Radiological and/or laboratory tests may be sometimes inadequate distinguishing glioblastoma from metastatic brain tumors. The aim of this study was to find possible predictive biomarkers produced from routine blood biochemistry analysis results evaluated preoperatively in each patient with solitary brain tumor in distinguishing glioblastoma from metastatic brain tumors as well as revealing short-term prognosis.
Patients admitted to neurosurgery clinic between January 2015 and September 2018 were included in this study and they were divided into GLIOMA (n=12) and METASTASIS (n=17) groups. Patients' data consisted of age, gender, Glasgow Coma Scale scores, duration of stay in hospital, Glasgow Outcome Scale (GOS) scores and histopathological examination reports, hemoglobin level, leukocyte, neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count results, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio values, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels were evaluated preoperatively.
The CRP levels of METASTASIS group (143.10 mg/L) were higher than those of GLIOMA group (23.90 mg/L); and it was 82% sensitive and 75% specific in distinguishing metastatic brain tumor from glioblastoma if CRP value was >55.00 mg/L. A positive correlation was determined between GOS score and hemoglobin level and between ESR and CRP values. However, GOS scores were negatively correlated with the ESR level and duration of stay in hospital.
Study results demonstrated that CRP values could be predictive biomarker in distinguishing metastatic brain tumor from glioblastoma. In addition, ESR, CRP, hemoglobin levels and duration of stay in hospital could be prognostic biomarkers in predicting short-term prognosis of patients with solitary brain tumor.
放射学和/或实验室检查有时可能不足以区分胶质母细胞瘤和脑转移瘤。本研究的目的是从每位孤立性脑肿瘤患者术前评估的常规血液生化分析结果中寻找可能的预测生物标志物，以区分胶质母细胞瘤和脑转移瘤，并揭示短期预后。
纳入2015年1月至2018年9月入住神经外科门诊的患者，分为胶质瘤组（n = 12）和转移瘤组（n = 17）。患者数据包括年龄、性别、格拉斯哥昏迷量表评分、住院时间、格拉斯哥预后量表（GOS）评分和组织病理学检查报告，术前评估血红蛋白水平、白细胞、中性粒细胞、淋巴细胞、单核细胞、嗜酸性粒细胞、嗜碱性粒细胞和血小板计数结果、中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值、C反应蛋白（CRP）和红细胞沉降率（ESR）水平。
转移瘤组的CRP水平（143.10mg/L）高于胶质瘤组（23.90mg/L）；如果CRP值>55.00mg/L，其区分脑转移瘤和胶质母细胞瘤的敏感性为82%，特异性为75%。GOS评分与血红蛋白水平之间以及ESR与CRP值之间存在正相关。然而，GOS评分与ESR水平和住院时间呈负相关。
研究结果表明，CRP值可能是区分脑转移瘤和胶质母细胞瘤的预测生物标志物。此外，ESR、CRP、血红蛋白水平和住院时间可能是预测孤立性脑肿瘤患者短期预后的预后生物标志物。
